1
|
Jiang XY, Shi LP, Zhu JL, Bai RR, Xie T. Elemene Antitumor Drugs Development Based on "Molecular Compatibility Theory" and Clinical Application: A Retrospective and Prospective Outlook. Chin J Integr Med 2024; 30:62-74. [PMID: 37882911 DOI: 10.1007/s11655-023-3714-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2023] [Indexed: 10/27/2023]
Abstract
Elemene, derived from Curcuma wenyujin, one of the "8 famous genuine medicinal materials of Zhejiang province," exhibits remarkable antitumor activity. It has gained wide recognition in clinical practice for effectiveness on tumors. Dr. XIE Tian, introduced the innovative concept of "molecular compatibility theory" by combining Chinese medicine principles, specifically the "monarch, minister, assistant, and envoy" theory, with modern biomedical technology. This groundbreaking approach, along with a systematic analysis of Chinese medicine and modern biomedical knowledge, led to the development of elemene nanoliposome formulations. These novel formulations offer numerous advantages, including low toxicity, well-defined composition, synergistic effects on multiple targets, and excellent biocompatibility. Following the principles of the "molecular compatibility theory", further exploration of cancer treatment strategies and methods based on elemene was undertaken. This comprehensive review consolidates the current understanding of elemene's potential antitumor mechanisms, recent clinical investigations, advancements in drug delivery systems, and structural modifications. The ultimate goal of this review is to establish a solid theoretical foundation for researchers, empowering them to develop more effective antitumor drugs based on the principles of "molecular compatibility theory".
Collapse
Affiliation(s)
- Xiao-Ying Jiang
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China
- Key Laboratory of Elemene Class Anti-cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China
- Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China
- Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China
| | - Li-Ping Shi
- Good Clinical Practice Center, Affliliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210000, China
| | - Jun-Long Zhu
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China
- Key Laboratory of Elemene Class Anti-cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China
- Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China
- Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China
| | - Ren-Ren Bai
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
- Key Laboratory of Elemene Class Anti-cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
- Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
- Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China.
| | - Tian Xie
- School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China.
- Key Laboratory of Elemene Class Anti-cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
- Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
- Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China.
| |
Collapse
|
2
|
Cao LY, Xu JY, Zhuo XT, Zhang W, Wei LJ, Dong JH, Bai RR, Wang X, Jiang YY, Wang YJ, Ye XY, Xie T, Huang ZH. 2,2'-((1R,3R,4S)-4-methyl-4-vinylcyclohexane-1,3-diyl) bis(prop-2-en-1-amine), a bisamino derivative of β-Elemene, inhibits glioblastoma growth through downregulation of YAP signaling. Am J Cancer Res 2022; 12:5484-5499. [PMID: 36628286 PMCID: PMC9827083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Accepted: 11/20/2022] [Indexed: 01/12/2023] Open
Abstract
β-Elemene, a compound extracted from Chinese herb Curcuma wenyujin, has been demonstrated with antitumor effects in various cancers, including glioblastoma (GBM), a primary brain tumor with high morbidity and mortality. In this study, we reported a bisamino derivative of β-Elemene, 2, 2'-((1R, 3R, 4S)-4-methyl-4-vinylcyclohexane-1, 3-diyl) bis(prop-2-en-1-amine) (compound 1), displayed a better anti-GBM effect than β-Elemene with lower concentration. GBM cell lines (C6 and U87) were treated with compound 1 and subsequently analyzed by several assays. Compound 1 significantly inhibited the migration of C6 and U87 cells based on wound healing assay, transwell assay and inverted migration assay. Furthermore, colony formation assay, immunostaining and flow cytometry assays revealed that compound 1 significantly inhibited the proliferation of GBM cells. In addition, compound 1 induced the apoptosis of GBM cells. Mechanistically, we found Yes-associated protein (YAP) was down-regulated in compound 1-treated GBM cells, and the overexpression of YAP partially rescued the anti-GBM effects of compound 1. Finally, compound 1 suppresses the GBM growth in xenograft model through inactivation YAP signaling. Taken together, these results reveal that a novel derivative of β-Elemene, compound 1, exhibits more potent anti-GBM activity than β-Elemene through inactivating YAP signaling pathway, which will provide novel strategies for the treatment of GBM.
Collapse
Affiliation(s)
- Li-Ying Cao
- Laboratory of Aging and Cancer Biology of Zhejiang Province, School of Basic Medical Sciences, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Jia-Yun Xu
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Xiao-Tao Zhuo
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Wei Zhang
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Li-Jia Wei
- Laboratory of Aging and Cancer Biology of Zhejiang Province, School of Basic Medical Sciences, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Jian-Hong Dong
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Ren-Ren Bai
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Xin Wang
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Yuan-Yuan Jiang
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Yong-Jie Wang
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Xiang-Yang Ye
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Tian Xie
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| | - Zhi-Hui Huang
- School of Pharmacy, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal UniversityHangzhou 311121, Zhejiang, China
| |
Collapse
|
3
|
Abstract
Natural products have been an important source of new drugs, which also played a dominant role in the discovery and research of new drugs for the treatment of hypertension. This review article reviews the recent progress in the research and development of natural lead compounds with antihypertensive activity, including alkaloids, diterpenes, coumarins, flavonoids, and peptides. We summarized their structures, sources, as well as the antihypertensive mechanisms. These information provides instructive reference for the following structural modifications and optimization.
Collapse
Affiliation(s)
- Ren-Ren Bai
- School of Medicine, Emory University, Atlanta 30322, GA, USA; Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
| | - Xiao-Ming Wu
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
| | - Jin-Yi Xu
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
| |
Collapse
|